18889881171
Kalkine 0
countryflagUS

Agios Pharm

Healthcare US AGIO

34.47USD
-0.03(0.09%)

Last update at 2025-06-13T16:45:00Z

Day Range

33.7534.89
LowHigh

52 Week Range

20.9662.58
LowHigh

Fundamentals

  • Previous Close 34.50
  • Market Cap2773.95M
  • Volume170348
  • P/E Ratio4.17
  • Dividend Yield-%
  • EBITDA-401.28800M
  • Revenue TTM32.87M
  • Revenue Per Share TTM0.58
  • Gross Profit TTM 12.54M
  • Diluted EPS TTM11.66

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -231.80100M -356.51000M -327.37000M -411.47200M -346.02800M
Minority interest - - - - -
Net income -74.55500M 1604.71M -335.21800M -396.61100M -346.02800M
Selling general administrative 121.67M 121.44M 149.07M 132.03M 114.14M
Selling and marketing expenses - - - - -
Gross profit 12.54M 0.04M 200.39M 116.59M 92.99M
Reconciled depreciation 8.56M 9.24M 9.98M 8.09M 7.17M
Ebit -389.04700M -378.41800M -316.14900M -426.33300M -369.65100M
Ebitda -526.75100M -385.05700M -309.53800M -418.24600M -362.47900M
Depreciation and amortization -137.70400M -6.63900M 6.61M 8.09M 7.17M
Non operating income net other 29.39M 21.91M 6.61M 14.86M 16.45M
Operating income -389.04700M -378.41800M -316.14900M -426.33300M -362.47900M
Other operating expenses 403.29M 378.42M 519.35M 544.25M 456.87M
Interest expense 12.79M 0.84M 17.83M 14.86M 16.45M
Tax provision - - - - -
Interest income 12.79M 0.84M 6.61M 14.86M 16.45M
Net interest income 12.79M 0.84M -11.22100M 14.86M 16.45M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -157.24600M -1977.94000M 7.85M -14.86100M 32.90M
Total revenue 14.24M 0.04M 203.20M 117.91M 94.39M
Total operating expenses 401.58M 378.42M 516.54M 542.93M 455.47M
Cost of revenue 1.70M 0.00071M 2.81M 1.32M 1.40M
Total other income expense net 157.25M 21.91M -11.22100M 14.86M 16.45M
Discontinued operations - 1961.22M 1961.22M 1961.22M 1961.22M
Net income from continuing ops -231.80100M -356.51000M -309.53800M -411.47200M -346.02800M
Net income applicable to common shares -231.80100M 1604.71M -327.37000M -411.47200M -346.02800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 937.12M 1238.72M 1437.74M 852.95M 890.74M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 35.02M 38.95M 11.82M -73.95700M 24.18M
Total liab 126.10M 137.90M 145.76M 453.45M 250.21M
Total stockholder equity 811.02M 1100.81M 1291.97M 399.50M 640.53M
Deferred long term liab - - - - -
Other current liab 43.17M 30.35M 31.97M 60.14M 53.14M
Common stock 0.07M 0.07M 0.07M 0.07M 0.07M
Capital stock 0.07M 0.07M 0.07M 0.07M 0.07M
Retained earnings -822.64900M -470.56100M -238.76000M -1843.47500M -1516.10500M
Other liab - 3.28M - 261.27M 50.58M
Good will - - - - -
Other assets - 3.96M 2.90M 1.12M -
Cash 88.20M 139.26M 203.13M 127.44M 80.93M
Cash and equivalents - - - - -
Total current liabilities 67.95M 62.63M 59.83M 94.39M 92.89M
Current deferred revenue - - - - 10.93M
Net debt -16.20900M -53.60000M -106.03200M -22.23700M 32.73M
Short term debt 15.01M 13.66M 11.16M 7.41M 6.92M
Short long term debt - - - - -
Short long term debt total 72.00M 85.66M 97.09M 105.20M 113.66M
Other stockholder equity 1634.04M 1583.84M 1531.86M 2242.80M 2156.36M
Property plant equipment - 22.99M 28.92M 32.29M 31.47M
Total current assets 833.84M 832.77M 1064.23M 636.68M 611.70M
Long term investments 29.43M 313.87M 266.38M 97.61M 152.93M
Net tangible assets - 1100.81M 1291.97M 399.50M 640.53M
Short term investments 688.72M 643.86M 816.89M 445.49M 483.95M
Net receivables 2.81M 2.21M 4.38M 25.40M 15.32M
Long term debt - - - - -
Inventory 19.08M 8.49M 16.19M 14.70M 7.33M
Accounts payable 9.78M 18.62M 16.70M 26.84M 21.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.44100M -12.53500M -1.19800M 0.10M 0.20M
Additional paid in capital - - - - -
Common stock total equity - 0.07M 0.07M 0.07M 0.07M
Preferred stock total equity - - - - -
Retained earnings total equity - -470.56100M -238.76000M -1843.47500M -1516.10500M
Treasury stock - -802.48600M -802.48600M - -
Accumulated amortization - - - - -
Non currrent assets other 4.06M 3.96M 2.90M 1.12M 94.64M
Deferred long term asset charges - - - - -
Non current assets total 103.28M 405.95M 373.50M 216.28M 279.04M
Capital lease obligations 72.00M 85.66M 97.09M 105.20M 113.66M
Long term debt total - - - - 0.67M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 243.26M -548.41700M 90.66M 103.61M -266.83900M
Change to liabilities 4.82M 1.93M 16.65M 10.95M 3.13M
Total cashflows from investing activities 243.26M 1248.78M 75.75M 91.44M -273.82500M
Net borrowings -0.33100M -0.57800M -0.33600M -0.11300M -0.11300M
Total cash from financing activities 2.35M -765.76800M 261.52M 289.61M 546.02M
Change to operating activities -9.17100M -34.30700M 2.03M -7.37000M 9.69M
Net income -231.80100M -356.51000M -327.37000M -411.47200M -346.02800M
Change in cash -63.86700M 75.69M 46.51M 10.43M -32.22200M
Begin period cash flow 203.13M 127.44M 80.93M 70.50M 102.72M
End period cash flow 139.26M 203.13M 127.44M 80.93M 70.50M
Total cash from operating activities -309.47800M -407.32000M -290.75900M -370.62200M -304.42100M
Issuance of capital stock - 0.00000M 0.00000M 277.20M 516.21M
Depreciation 8.56M 9.24M 9.98M 8.09M 7.17M
Other cashflows from investing activities 132.75M 1802.94M 1802.94M 103.61M -266.83900M
Dividends paid - - - - -
Change to inventory -8.49200M -8.49200M -7.36700M -6.46200M -0.86900M
Change to account receivables -2.20600M -4.37800M -10.06000M -3.61900M -6.10200M
Sale purchase of stock 2.68M -802.48600M 11.32M 289.72M 546.02M
Other cashflows from financing activities 2.68M 37.30M 261.85M 12.52M 29.82M
Change to netincome 49.25M -39.71400M 75.12M 73.42M 73.38M
Capital expenditures 4.88M 5.74M 14.91M 12.17M 6.99M
Change receivables -2.20600M - - - -
Cash flows other operating -360.21600M -385.72400M -60.79900M -41.95400M -37.37100M
Exchange rate changes - - - - -
Cash and cash equivalents changes -63.86700M 75.69M 46.51M 10.43M -32.22200M
Change in working capital -16.43300M -36.82200M -71.03700M -45.99900M -35.10500M
Stock based compensation 49.30M 53.51M 75.12M 72.37M 73.36M
Other non cash items -119.10400M 9.54M 19.52M 8.53M -3.81700M
Free cash flow -314.35900M -413.06100M -305.66800M -382.79300M -311.40700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGIO
Agios Pharm		 -0.03 0.09% 34.47 4.17 2.47 84.39 2.16 78.23 -2.3282
NVO
Novo Nordisk A/S		 -0.56 0.69% 80.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.41 0.51% 80.59 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.29 0.28% 458.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.82 0.54% 524.66 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharm

88 Sidney Street, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. Bruce D. Car DACVP, Ph.D. Consultant 1961
Dr. Sarah Gheuens M.D., Ph.D. Chief Medical Officer and Head of R&D 1980
Ms. Richa Poddar Chief Commercial Officer 1982
Mr. Brian M. Goff M.B.A. CEO & Director 1969
Dr. Lewis Clayton Cantley Ph.D. Co-Founder & Member of Scientific Advisory Board 1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. Co-Founder & Member of Scientific Advisory Board 1946
Dr. Craig B. Thompson M.D. Co-Founder & Chairman of Scientific Advisory Board 1953
Dr. Shin-San Su Ph.D. Co-Founder & Member of Scientific Advisory Board 1956
Ms. Cecilia Jones Chief Financial Officer 1975
Mr. T. J. Washburn Jr. Principal Accounting Officer 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.